Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors

Current Medicinal Chemistry

Volumn 19, Issue 9, 2012, Pages 1282-1294

  Ferraris, D V ^a   Shukla, K ^b   Tsukamoto, T ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

glutamate; Glutamate carboxypeptidase II (GCPII); metallopeptidase inhibitors; N acetylaspartylglutamate (NAAG); prostate specific membrane antigen (PSMA)

Indexed keywords

2 (3 MERCAPTOPROPYL) PENTANEDIOIC ACID; 2 (HYDROXY PENTAFLUOROPHENYLMETHYL PHOSPHINOYLMETHYL) PENTANEDIOIC ACID; 2 (HYDROXYCARBAMOYLMETHYL) PENTANEDIOIC ACID; 2 (THIOALKYL) PENTANEDIOIC ACID DERIVATIVE; 2 PHOSPHONOMETHYLPENTANEDIOIC ACID; 3[(3(4 CARBOXYPHENYL) 5 HYDROXYISOXAZOL 4 YL) METHYL] BENZOIC ACID; CAPTOPRIL; FOSINOPRIL; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; GPI 18431; GPI 78; N ACETYL LEVO ASPARTYL BETA LINKED LEVO GLUTAMATE; PHOSPHORAMIDIC ACID DERIVATIVE; PHOSPHORUS; QUISQUALIC ACID; THIOL; UNCLASSIFIED DRUG; UREA; ZINC BINDING PROTEIN; ZJ 43;

AMYOTROPHIC LATERAL SCLEROSIS; COCAINE DEPENDENCE; CRYSTALLOGRAPHY; DIABETIC NEUROPATHY; DRUG BIOAVAILABILITY; ENANTIOMER; ENZYME INHIBITION; HUMAN; IC 50; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; REVIEW; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

ANIMALS; DIPEPTIDES; ENZYME INHIBITORS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84858144242     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799462658     Document Type: Review

References (87)

1. Carter, R.E.; Coyle, J.T. In Handbook of Proteolytic Enzymes. Barrett, A.J.; Rawlings, N.D.; Woessner, J.F., Eds.; Academic: New York, 1998, pp 1434-1437.
2. Barinka, C.; Sacha, P.; Sklenar, J.; Man, P.; Bezouska, K.; Slusher, B.S.; Konvalinka, J. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci, 2004, 13, 1627-1635. (Pubitemid 38669250)
3. Rawlings, N.D.; Barrett, A.J. Structure of membrane glutamate carboxypeptidase. Biochim Biophys Acta, 1997, 1339, 247-252. (Pubitemid 27220250)
4. Robinson, M.B.; Blakely, R.D.; Couto, R.; Coyle, J.T. Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J. Biol. Chem., 1987, 262, 14498-14506. (Pubitemid 17157357)
5. Neale, J.H.; Olszewski, R.T.; Gehl, L.M.; Wroblewska, B.; Bzdega, T. The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol. Sci., 2005, 26, 477-484. (Pubitemid 41207880)
6. Carter, R.E.; Feldman, A.R.; Coyle, J.T. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 749-753. (Pubitemid 26041162)
7. Silver, D.A.; Pellicer, I.; Fair, W.R.; Heston, W.D.; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res, 1997, 3, 81-85. (Pubitemid 27079448)
8. Chang, S.S.; O'Keefe, D.S.; Bacich, D.J.; Reuter, V.E.; Heston, W.D.; Gaudin, P.B. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res, 1999, 5, 2674-2681. (Pubitemid 29493938)
9. Pinto, J.T.; Suffoletto, B.P.; Berzin, T.M.; Qiao, C.H.; Lin, S.; Tong, W.P.; May, F.; Mukherjee, B.; Heston, W.D. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res, 1996, 2, 1445-1451. (Pubitemid 126447436)
10. Zhou, J.; Neale, J.H.; Pomper, M.G.; Kozikowski, A.P. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat. Rev. Drug Discov., 2005, 4, 1015-1026.
11. Tsukamoto, T.; Wozniak, K.M.; Slusher, B.S. Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov Today, 2007, 12, 767-776. (Pubitemid 47362787)
12. Krapcho, J.; Turk, C.; Cushman, D.W.; Powell, J.R.; DeForrest, J.M.; Spitzmiller, E.R.; Karanewsky, D.S.; Duggan, M.; Rovnyak, G.; Schwartz, J.; et al. Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines. J Med Chem, 1988, 31, 1148-1160.
13. Jackson, P.F.; Cole, D.C.; Slusher, B.S.; Stetz, S.L.; Ross, L.E.; Donzanti, B.A.; Trainor, D.A. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J. Med. Chem., 1996, 39, 619-622. (Pubitemid 26041474)
14. Rojas, C.; Frazier, S.T.; Flanary, J.; Slusher, B.S. Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay. Anal. Biochem., 2002, 310, 50-54. (Pubitemid 35387330)
15. Vitharana, D.; France, J.E.; Scarpetti, D.; Bonneville, G.W.; Majer, P.; Tsukamoto, T. Synthesis and biological evaluation of (R)- and (S)-2-(phosphonomethyl)pentanedioic acids as inhibitors of glutamate carboxypeptidase II. Tetrahedron: Asymm., 2002, 13, 1609-1614.
16. Mesters, J.R.; Henning, K.; Hilgenfeld, R. Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. Acta Crystallogr D Biol Crystallogr, 2007, 63, 508-513. (Pubitemid 46465946)
17. Barinka, C.; Rovenska, M.; Mlcochova, P.; Hlouchova, K.; Plechanovova, A.; Majer, P.; Tsukamoto, T.; Slusher, B.S.; Konvalinka, J.; Lubkowski, J. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem, 2007, 50, 3267-3273. (Pubitemid 47065975)
18. Jackson, P.F.; Tays, K.L.; Maclin, K.M.; Ko, Y.S.; Li, W.; Vitharana, D.; Tsukamoto, T.; Stoermer, D.; Lu, X.C.; Wozniak, K.; Slusher, B.S. Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. J Med Chem, 2001, 44, 4170-4175. (Pubitemid 33095323)
19. Tang, H.; Brown, M.; Ye, Y.; Huang, G.; Zhang, Y.; Wang, Y.; Zhai, H.; Chen, X.; Shen, T.Y.; Tenniswood, M. Prostate targeting ligands based on N-acetylated alpha-linked acidic dipeptidase. Biochem Biophys Res Commun, 2003, 307, 8-14. (Pubitemid 36808529)
20. Ding, P.; Helquist, P.; Miller, M.J. Design, synthesis and pharmacological activity of novel enantiomerically pure phosphonic acid-based NAALADase inhibitors. Org Biomol Chem, 2007, 5, 826-831.
21. Ding, P.; Helquist, P.; Miller, M.J. Design and synthesis of a siderophore conjugate as a potent PSMA inhibitor and potential diagnostic agent for prostate cancer. Bioorg Med Chem, 2008, 16, 1648-1657. (Pubitemid 351233044)
22. Tsukamoto, T.; Flanary, J.M.; Rojas, C.; Slusher, B.S.; Valiaeva, N.; Coward, J.K. Phosphonate and phosphinate analogues of N-acylated gamma-glutamylglutamate. potent inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett, 2002, 12, 2189-2192. (Pubitemid 34804396)
23. Wu, L.Y.; Anderson, M.O.; Toriyabe, Y.; Maung, J.; Campbell, T.Y.; Tajon, C.; Kazak, M.; Moser, J.; Berkman, C.E. The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem, 2007, 15, 7434-7443. (Pubitemid 47539133)
24. Liu, T.; Toriyabe, Y.; Kazak, M.; Berkman, C.E. Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry, 2008, 47, 12658-12660.
25. Liu, T.; Wu, L.Y.; Kazak, M.; Berkman, C.E. Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate, 2008, 68, 955-964. (Pubitemid 351794160)
26. Lapi, S.E.; Wahnishe, H.; Pham, D.; Wu, L.Y.; Nedrow-Byers, J.R.; Liu, T.; Vejdani, K.; VanBrocklin, H.F.; Berkman, C.E.; Jones, E.F. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med, 2009, 50, 2042-2048.
27. Williams, A.J.; Lu, X.M.; Slusher, B.; Tortella, F.C. Electroencephalogram analysis and neuroprotective profile of the N-acetylated-alpha-linked acidic dipeptidase inhibitor, GPI5232, in normal and brain-injured rats. J. Pharmacol. Exp. Ther., 2001, 299, 48-57. (Pubitemid 32905117)
28. Slusher, B.S.; Vornov, J.J.; Thomas, A.G.; Hurn, P.D.; Harukuni, I.; Bhardwaj, A.; Traystman, R.J.; Robinson, M.B.; Britton, P.; Lu, X.C.; Tortella, F.C.; Wozniak, K.M.; Yudkoff, M.; Potter, B.M.; Jackson, P.F. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med., 1999, 5, 1396-1402.
29. Tsukamoto, T.; Majer, P.; Vitharana, D.; Ni, C.; Hin, B.; Lu, X.C.; Thomas, A.G.; Wozniak, K.M.; Calvin, D.C.; Wu, Y.; Slusher, B.S.; Scarpetti, D.; Bonneville, G.W. Enantiospecificity of glutamate carboxypeptidase II inhibition. J Med Chem, 2005, 48, 2319-2324. (Pubitemid 40516426)
30. Mesters, J.R.; Barinka, C.; Li, W.; Tsukamoto, T.; Majer, P.; Slusher, B.S.; Konvalinka, J.; Hilgenfeld, R. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J, 2006, 22, 1375-1384.
31. Nan, F.; Bzdega, T.; Pshenichkin, S.; Wroblewski, J.T.; Wroblewska, B.; Neale, J.H.; Kozikowski, A.P. Dual function glutamate-related ligands: discovery of a novel, potent inhibitor of glutamate carboxypeptidase II possessing mGluR3 agonist activity. J Med Chem, 2000, 43, 772-774. (Pubitemid 30152285)
32. Barinka, C.; Hlouchova, K.; Rovenska, M.; Majer, P.; Dauter, M.; Hin, N.; Ko, Y.S.; Tsukamoto, T.; Slusher, B.S.; Konvalinka, J.; Lubkowski, J. Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs. J Mol Biol, 2008, 376, 1438-1450.
33. Humblet, V.; Lapidus, R.; Williams, L.R.; Tsukamoto, T.; Rojas, C.; Majer, P.; Hin, B.; Ohnishi, S.; De Grand, A.M.; Zaheer, A.; Renze, J.T.; Nakayama, A.; Slusher, B.S.; Frangioni, J.V. High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostatespecific membrane antigen. Mol Imaging, 2005, 4, 448-462. (Pubitemid 43143785)
34. He, G.-X.; Krise, J.P.; Oliyai, R. In Prodrugs. Stella, V.J.; Borchardt, R.T.; Hageman, M.J.; Oliyai, R.; Maag, H.; Tilley, J.W., Eds.; Springer New York, 2007; Vol. V, pp 223-264.
35. Shiosaki, K.; Lin, C.W.; Leanna, M.R.; Morton, H.E.; Miller, T.R.; Witte, D.; Stashko, M.; Nadzan, A.M. Toward developing peptidomimetics: Successful replacement of backbone amide bonds in tetrapeptide-based CCK-A receptor agonists. Bioorg. Med. Chem. Lett., 1993, 3, 855-860. (Pubitemid 23149572)
36. Zhang, Y.; Li, D.; Houtman, J.C.; Witiak, D.T.; Seltzer, J.; Bertics, P.J.; Lauhon, C.T. Design, combinatorial chemical synthesis and in vitro characterization of novel urea based gelatinase inhibitors. Bioorg Med Chem Lett, 1999, 9, 2823-2826. (Pubitemid 29481170)
37. Myers, A.C.; Kowalski, J.A.; Lipton, M.A. Facile incorporation of urea pseudopeptides into protease substrate analogue inhibitors. Bioorg Med Chem Lett, 2004, 14, 5219-5222. (Pubitemid 39233398)
38. Kozikowski, A.P.; Nan, F.; Conti, P.; Zhang, J.; Ramadan, E.; Bzdega, T.; Wroblewska, B.; Neale, J.H.; Pshenichkin, S.; Wroblewski, J.T. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem, 2001, 44, 298-301. (Pubitemid 32113579)
39. Kozikowski, A.P.; Zhang, J.; Nan, F.; Petukhov, P.A.; Grajkowska, E.; Wroblewski, J.T.; Yamamoto, T.; Bzdega, T.; Wroblewska, B.; Neale, J.H. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem, 2004, 47, 1729-1738. (Pubitemid 38380916)
40. Maresca, K.P.; Hillier, S.M.; Femia, F.J.; Keith, D.; Barone, C.; Joyal, J.L.; Zimmerman, C.N.; Kozikowski, A.P.; Barrett, J.A.; Eckelman, W.C.; Babich, J.W. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem, 2009, 52, 347-357.
41. Foss, C.A.; Mease, R.C.; Fan, H.; Wang, Y.; Ravert, H.T.; Dannals, R.F.; Olszewski, R.T.; Heston, W.D.; Kozikowski, A.P.; Pomper, M.G. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res, 2005, 11, 4022-4028. (Pubitemid 40791565)
42. Mease, R.C.; Dusich, C.L.; Foss, C.A.; Ravert, H.T.; Dannals, R.F.; Seidel, J.; Prideaux, A.; Fox, J.J.; Sgouros, G.; Kozikowski, A.P.; Pomper, M.G. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res, 2008, 14, 3036-3043.
43. Banerjee, S.R.; Foss, C.A.; Castanares, M.; Mease, R.C.; Byun, Y.; Fox, J.J.; Hilton, J.; Lupold, S.E.; Kozikowski, A.P.; Pomper, M.G. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem, 2008, 51, 4504-4517.
44. Chen, Y.; Foss, C.A.; Byun, Y.; Nimmagadda, S.; Pullambhatla, M.; Fox, J.J.; Castanares, M.; Lupold, S.E.; Babich, J.W.; Mease, R.C.; Pomper, M.G. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem, 2008, 51, 7933-7943.
45. Chen, Y.; Dhara, S.; Banerjee, S.R.; Byun, Y.; Pullambhatla, M.; Mease, R.C.; Pomper, M.G. A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun, 2009, 390, 624-629.
46. Banerjee, S.R.; Pullambhatla, M.; Byun, Y.; Nimmagadda, S.; Green, G.; Fox, J.J.; Horti, A.; Mease, R.C.; Pomper, M.G. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem, 2010, 53, 5333-5341.
47. Chandran, S.S.; Banerjee, S.R.; Mease, R.C.; Pomper, M.G.; Denmeade, S.R. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol Ther, 2008, 7, 974-982.
48. Kularatne, S.A.; Wang, K.; Santhapuram, H.K.; Low, P.S. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm, 2009, 6, 780-789.
49. Kularatne, S.A.; Zhou, Z.; Yang, J.; Post, C.B.; Low, P.S. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents. Mol Pharm, 2009, 6, 790-800.
50. Kularatne, S.A.; Venkatesh, C.; Santhapuram, H.K.; Wang, K.; Vaitilingam, B.; Henne, W.A.; Low, P.S. Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs. J Med Chem, 2010, 53, 7767-7777.
51. Barinka, C.; Byun, Y.; Dusich, C.L.; Banerjee, S.R.; Chen, Y.; Castanares, M.; Kozikowski, A.P.; Mease, R.C.; Pomper, M.G.; Lubkowski, J. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem, 2008, 51, 7737-7743.
52. Klusak, V.; Barinka, C.; Plechanovova, A.; Mlcochova, P.; Konvalinka, J.; Rulisek, L.; Lubkowski, J. Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods. Biochemistry, 2009, 48, 4126-4138.
53. Wang, H.; Byun, Y.; Barinka, C.; Pullambhatla, M.; Bhang, H.E.; Fox, J.J.; Lubkowski, J.; Mease, R.C.; Pomper, M.G. Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies. Bioorg Med Chem Lett, 2010, 20, 392-397.
54. Zhang, A.X.; Murelli, R.P.; Barinka, C.; Michel, J.; Cocleaza, A.; Jorgensen, W.L.; Lubkowski, J.; Spiegel, D.A. A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc, 2010, 132, 12711-12716.
55. Olszewski, R.T.; Bukhari, N.; Zhou, J.; Kozikowski, A.P.; Wroblewski, J.T.; Shamimi-Noori, S.; Wroblewska, B.; Bzdega, T.; Vicini, S.; Barton, F.B.; Neale, J.H. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem, 2004, 89, 876-885. (Pubitemid 38684735)
56. Zhong, C.; Zhao, X.; Sarva, J.; Kozikowski, A.; Neale, J.H.; Lyeth, B.G. NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats. J Neurotrauma, 2005, 22, 266-276. (Pubitemid 40333520)
57. Yamamoto, T.; Hirasawa, S.; Wroblewska, B.; Grajkowska, E.; Zhou, J.; Kozikowski, A.; Wroblewski, J.; Neale, J.H. Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model. Eur J Neurosci, 2004, 20, 483-494. (Pubitemid 38969633)
58. Zhong, C.; Zhao, X.; Van, K.C.; Bzdega, T.; Smyth, A.; Zhou, J.; Kozikowski, A.P.; Jiang, J.; O'Connor W, T.; Berman, R.F.; Neale, J.H.; Lyeth, B.G. NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. J Neurochem, 2006, 97, 1015-1025.
59. Saito, O.; Aoe, T.; Kozikowski, A.; Sarva, J.; Neale, J.H.; Yamamoto, T. Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain. Can J Anaesth, 2006, 53, 891-898. (Pubitemid 44696513)
60. Yamamoto, T.; Saito, O.; Aoe, T.; Bartolozzi, A.; Sarva, J.; Zhou, J.; Kozikowski, A.; Wroblewska, B.; Bzdega, T.; Neale, J.H. Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats. Eur J Neurosci, 2007, 25, 147-158. (Pubitemid 46098894)
61. Feng, J.F.; Van, K.C.; Gurkoff, G.G.; Kopriva, C.; Olszewski, R.T.; Song, M.; Sun, S.; Xu, M.; Neale, J.H.; Yuen, P.W.; Lowe, D.A.; Zhou, J.; Lyeth, B.G. Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI. Brain Res, 2011, 1395, 62-73.
62. Majer, P.; Jackson, P.F.; Delahanty, G.; Grella, B.S.; Ko, Y.S.; Li, W.; Liu, Q.; Maclin, K.M.; Polakova, J.; Shaffer, K.A.; Stoermer, D.; Vitharana, D.; Wang, E.Y.; Zakrzewski, A.; Rojas, C.; Slusher, B.S.; Wozniak, K.M.; Burak, E.; Limsakun, T.; Tsukamoto, T. Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J. Med. Chem., 2003, 46, 1989-1996. (Pubitemid 36532241)
63. Cushman, D.W.; Cheung, H.S.; Sabo, E.F.; Ondetti, M.A. Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry, 1977, 16, 5484-5491. (Pubitemid 8254139)
64. Ondetti, M.A.; Condon, M.E.; Reid, J.; Sabo, E.F.; Cheung, H.S.; Cushman, D.W. Design of potent and specific inhibitors of carboxypeptidases A and B. Biochemistry, 1979, 18, 1427-1430.
65. Ghadge, G.D.; Slusher, B.S.; Bodner, A.; Canto, M.D.; Wozniak, K.; Thomas, A.G.; Rojas, C.; Tsukamoto, T.; Majer, P.; Miller, R.J.; Monti, A.L.; Roos, R.P. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc. Natl. Acad. Sci. U S A, 2003, 100, 9554-9559. (Pubitemid 37033966)
66. Zhang, W.; Murakawa, Y.; Wozniak, K.M.; Slusher, B.; Sima, A.A. The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. J Neurol Sci, 2006, 247, 217-223. (Pubitemid 44301265)
67. Peng, X.Q.; Li, J.; Gardner, E.L.; Ashby, C.R., Jr.; Thomas, A.; Wozniak, K.; Slusher, B.S.; Xi, Z.X. Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats. Eur J Pharmacol, 2010, 627, 156-161.
68. Takatsu, Y.; Fujita, Y.; Tsukamoto, T.; Slusher, B.S.; Hashimoto, K. Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpine-induced prepulse inhibition deficits in mice. Brain Res, 2011, 1371, 82-86.
69. van der Post, J.P.; de Visser, S.J.; de Kam, M.L.; Woelfler, M.; Hilt, D.C.; Vornov, J.; Burak, E.S.; Bortey, E.; Slusher, B.S.; Limsakun, T.; Cohen, A.F.; van Gerven, J.M. The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. Br J Clin Pharmacol, 2005, 60, 128-136.
70. Majer, P.; Hin, B.; Stoermer, D.; Adams, J.; Xu, W.; Duvall, B.R.; Delahanty, G.; Liu, Q.; Stathis, M.J.; Wozniak, K.M.; Slusher, B.S.; Tsukamoto, T. Structural Optimization of Thiol-Based Inhibitors of Glutamate Carboxypeptidase II by Modification of the P1' Side Chain. J Med Chem, 2006, 49, 2876-2885.
71. Grella, B.; Adams, J.; Berry, J.F.; Delahanty, G.; Ferraris, D.V.; Majer, P.; Ni, C.; Shukla, K.; Shuler, S.A.; Slusher, B.S.; Stathis, M.; Tsukamoto, T. The discovery and structure-activity relationships of indole-based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett, 2010, 20, 7222-7225.
72. Jaffe, I.A. Adverse effects profile of sulfhydryl compounds in man. Am J Med, 1986, 80, 471-476. (Pubitemid 16098784)
73. Skotnicki, J.S.; Zask, A.; Nelson, F.C.; Albright, J.D.; Levin, J.I. Design and synthetic considerations of matrix metalloproteinase inhibitors. Ann N Y Acad Sci, 1999, 878, 61-72. (Pubitemid 29353560)
74. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylase inhibitors: from bench to clinic. J Med Chem, 2008, 51, 1505-1529. (Pubitemid 351438836)
75. Stoermer, D.; Liu, Q.; Hall, M.R.; Flanary, J.M.; Thomas, A.G.; Rojas, C.; Slusher, B.S.; Tsukamoto, T. Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. Bioorg. Med. Chem. Lett., 2003, 13, 2097-2100. (Pubitemid 36694282)
76. Supuran, C.T. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett, 2010, 20, 3467-3474.
77. Blank, B.R.; Alayoglu, P.; Engen, W.; Choi, J.K.; Berkman, C.E.; Anderson, M.O. N-substituted glutamyl sulfonamides as inhibitors of glutamate carboxypeptidase II (GCP2). Chem Biol Drug Des, 2011, 77, 241-247.
78. Teus, M.; Jirgensons, A.; Dambrova, M.; Mezhapuke, R. Synthesis and GCP II inhibitory activity of 4[4-(3-bromobenzyl)-5-hydroxyisoxazol-3-yl]benzoic acid heterocyclic analogs. Chem. Heterocycl. Compd., 2007, 43, 1440-1444.
79. Teus, M.; Jirgensons, A.; Dambrova, M.; Mezhapuke, R.; Parsons, C.G.; Danysz, W. Identification of GCP II Inhibitors Based on 4-Arylmethyl-3-(4- carboxyphenyl)-5-hydroxyisoxazole Scaffold. Lett. Drug Des. Discov., 2009, 6, 29-32.
80. Serval, V.; Barbeito, L.; Pittaluga, A.; Cheramy, A.; Lavielle, S.; Glowinski, J. Competitive inhibition of N-acetylated-alpha-linked acidic dipeptidase activity by N-acetyl-L-aspartyl-beta-linked L-glutamate. J Neurochem, 1990, 55, 39-46.
81. Subasinghe, N.; Schulte, M.; Chan, M.Y.; Roon, R.J.; Koerner, J.F.; Johnson, R.L. Synthesis of acyclic and dehydroaspartic acid analogues of Ac-Asp-Glu-OH and their inhibition of rat brain N-acetylated alpha-linked acidic dipeptidase (NAALA dipeptidase). J Med Chem, 1990, 33, 2734-2744. (Pubitemid 20312136)
82. Ding, P.; Miller, M.J.; Chen, Y.; Helquist, P.; Oliver, A.J.; Wiest, O. Syntheses of conformationally constricted molecules as potential NAALADase/PSMA inhibitors. Org. Lett., 2004, 6, 1805-1808. (Pubitemid 38748322)
83. Watkins, J.C. l-glutamate as a central neurotransmitter: looking back. Biochem Soc Trans, 2000, 28, 297-309.
84. Robinson, M.B.; Blakely, R.D.; Coyle, J.T. Quisqualate selectively inhibits a brain peptidase which cleaves N-acetyl-L-aspartyl-L-glutamate in vitro. Eur J Pharmacol, 1986, 130, 345-347. (Pubitemid 17193226)
85. 111In capromab pendetide in subjects with metastatic prostate cancer. Indentifier: NCT00992745 (accessed Aug 4, 2011).
86. Gupta, A.; Gupta, A.K.; Seshadri, K. Structural models in the assessment of protein druggability based on HTS data. J Comput Aided Mol Des, 2009, 23, 583-592.
87. Bařinka, C.; Rojas, C.; Slusher, B.; Pomper, M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr. Med. Chem. 2012, 19(6), 856-870.